Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Clinical Investigation of AcrySof® IQ PanOptix™ IOL Model TFNT00
NCT03280108 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this clinical study is to compare the visual outcomes of the AcrySof IQ PanOptix Multifocal Intraocular Lens (IOL) Model TFNT00 against that of a monofocal lens, the AcrySof Monofocal IOL Model SN60AT, in order to demonstrate comparable distance vision and superior near and intermediate vision.
Conditions Studied
Interventions
- DEVICE AcrySof IQ PanOptix Multifocal IOL
- DEVICE AcrySof Monofocal IOL
Study Locations (12)
Texas
- Alcon Investigative Site — Houston
- Alcon Investigative Site — Hurst
- Alcon Investigative Site — Nacogdoches
Florida
- Alcon Investigative Site — Mt. Dora
- Alcon Investigative Site — Panama City
California
- Alcon Investigative Site — Fresno
New York
- Alcon Investigative Site — Poughkeepsie
South Carolina
- Alcon Investigative Site — Mt. Pleasant
South Dakota
- Alcon Investigative Site — Sioux Falls
Tennessee
- Alcon Investigative Site — Nashville
Utah
- Alcon Investigative Site — Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2017-11-01 |
| Est. Completion | 2018-09-27 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03280108
The ClinicalTrials.gov registry entry for NCT03280108 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alcon Research, which has 111 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Cataract appearing as the primary indexed condition, and to 2 interventions — of which AcrySof IQ PanOptix Multifocal IOL is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT03280108 reports 12 study locations spanning 9 distinct geographic areas — top geographies include Texas, Florida, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT03280108 about?
NCT03280108 is a clinical study titled "Clinical Investigation of AcrySof® IQ PanOptix™ IOL Model TFNT00". The purpose of this clinical study is to compare the visual outcomes of the AcrySof IQ PanOptix Multifocal Intraocular Lens (IOL) Model TFNT00 against that of a monofocal lens, the AcrySof Monofocal IOL Model SN60AT, in order to demonstrate comparable distance vision and superior near and intermedia...
What is the current status of trial NCT03280108?
This trial is currently completed. It is a NA study. The enrollment target is 250 participants. The study started on 2017-11-01. Estimated completion is 2018-09-27.
What conditions does trial NCT03280108 study?
This clinical trial studies the following conditions: Cataract. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT03280108?
The interventions under investigation include: AcrySof IQ PanOptix Multifocal IOL (DEVICE), AcrySof Monofocal IOL (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT03280108?
This trial is sponsored by Alcon Research, which has 111 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT03280108 being conducted?
This trial has 12 study locations across California, Florida, New York, South Carolina, South Dakota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.